# Dabigatran Versus Warfarin With NVAF Who Undergo PCI

Study · id `cardio:ct-nct03536611` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03536611](<https://clinicaltrials.gov/study/NCT03536611>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03536611

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1120 participants.

## Technical summary

Registry record NCT03536611. Randomized; single masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1120 participants (planned count; ClinicalTrials.gov record NCT03536611, source copy `cardio:ctgov-nct03536611-2019-01-04`, retrieved 2026-10-26)
- Started: 2018-09-01 (actual) (ClinicalTrials.gov record NCT03536611, source copy `cardio:ctgov-nct03536611-2019-01-04`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03536611, source copy `cardio:ctgov-nct03536611-2019-01-04`, retrieved 2026-10-26)
- Completion: 2020-06-30 (anticipated) (ClinicalTrials.gov record NCT03536611, source copy `cardio:ctgov-nct03536611-2019-01-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03536611, source copy `cardio:ctgov-nct03536611-2019-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03536611-2019-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dabigatran Versus Warfarin With NVAF Who Undergo PCI
- Acronym: COACH-AF-PCI
- Condition: Atrial Fibrillation
- Condition: Coronary Artery Disease
- Intervention (Drug): dabigatran
- Intervention (Drug): warfarin
- Lead sponsor: Shenyang Northern Hospital
- Lead sponsor class: OTHER
- Collaborator: Beijing Anzhen Hospital
- Collaborator class: OTHER
- Collaborator: Second Affiliated Hospital of Third Military Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Shenyang Northern Hospital (`cardio:org-shenyang-northern-hospital`)
- Registry lists this organization as a collaborator: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI) (`cardio:pubmed-41254594`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e20ed4421e8fbc1ea1761cf827fcd02c0d9575ea938ffdbf123d0c8b393a2147
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
